

Author: Pachler Karin Ketterl Nina Desgeorges Alexandre Dunai Zsuzsanna A. Laner-Plamberger Sandra Streif Doris Strunk Dirk Rohde Eva Gimona Mario
Publisher: MDPI
E-ISSN: 1422-0067|18|7|1413-1413
ISSN: 1422-0067
Source: International Journal of Molecular Sciences, Vol.18, Iss.7, 2017-07, pp. : 1413-1413
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The regenerative and immunomodulatory activity of mesenchymal stromal cells (MSCs) is partially mediated by secreted vesicular factors. Extracellular vesicles (EVs) exocytosed by MSCs are gaining increased attention as prospective non-cellular therapeutics for a variety of diseases. However, the lack of suitable in vitro assays to monitor the therapeutic potential of EVs currently restricts their application in clinical studies. We have evaluated a dual in vitro immunomodulation potency assay that reproducibly reports the inhibitory effect of MSCs on induced T-cell proliferation and the alloantigen-driven mixed leukocyte reaction of pooled peripheral blood mononuclear cells in a dose-dependent manner. Phytohemagglutinin-stimulated T-cell proliferation was inhibited by MSC-derived EVs in a dose-dependent manner comparable to MSCs. In contrast, inhibition of alloantigen-driven mixed leukocyte reaction was only observed for MSCs, but not for EVs. Our results support the application of a cell-based in vitro potency assay for reproducibly determining the immunomodulatory potential of EVs. Validation of this assay can help establish reliable release criteria for EVs for future clinical studies.
Related content


By Börger Verena Bremer Michel Ferrer-Tur Rita Gockeln Lena Stambouli Oumaima Becic Amina Giebel Bernd
International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. :




By Cosenza Stella Ruiz Maxime Maumus Marie Jorgensen Christian Noël Danièle
International Journal of Molecular Sciences, Vol. 18, Iss. 4, 2017-04 ,pp. :

